Nano-formulation of darkness hormone could be therapeutic solution for Parkinson's disease
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
This approval is a significant achievement in expanding the availability of this critical therapeutic,
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
SPARC to receive 55% equity in Tiller Therapeutics
Subscribe To Our Newsletter & Stay Updated